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Introduction
In postmenopausal women, cardiovascular disease (CVD) 
is major reason of morbidity and mortality.1 In the past, 
menopausal hormonal therapy (MHT) had been regarded 
to have effect of preventing CVD, but several randomized 
controlled trials (RCTs) have shown that MHT does not 
reduce or slow the progression of established CVD.2~5 
Nowadays MHT is not recommended for the primary and 
secondary prevention of CVD. 
Unlike RCTs, most observational studies support 
potential benefits of MHT in reducing risk of CVD. 
Furthermore, reanalysis of RCT showed that starting MHT 
closer to menopause tended to reduce the risk of CVD 
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Objectives: Decreased renal function is associated with increased cardiovascular risk. Our study was planned to verify the 
association of decreased renal function and subclinical coronary atherosclerosis in postmenopausal women.
Methods: We performed a retrospective review of 251 Korean postmenopausal women who visited the health promotion center 
for a routine health checkup. Estimated glomerular filtration rate (eGFR) was used to show renal function, which was estimated by 
calculated using the Cockcroft-Gault (CG) and the modification of diet in renal disease (MDRD) formulas. Coronary atherosclerosis 
was assessed by 64-row multidetector computed tomography.
Results: Women with reduced eGFR (< 60 mL/minute/1.73 m2) had significantly higher brachial-ankle pulse wave velocity (baPWV) 
than women with normal eGFR (≥ 60 mL/minute/1.73 m2). The eGFR was negatively correlated with baPWV (r = -0.352, P < 0.001), 
significantly. The eGFR was lower in women with coronary atherosclerosis than in normal control women, markedly. Reduced eGFR 
was significantly associated with the presence of coronary atherosclerosis (odds ratio [OR] = 7.528, 95% confidence interval [CI] = 
2.728-20.772, P < 0.001).
Conclusions: Decreased eGFR was closely associated with increased arterial stiffness and coronary atherosclerosis in 
postmenopausal women. Evaluating subclinical atherosclerosis by screening the renal function in postmenopausal women may be 
helpful screening high risk group and considering starting menopausal hormone therapy before atherosclerosis development. (J 
Menopausal Med 2016;22:167-173)
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compared with starting MHT distant from menopause, 
which suggests determining start point of MHT could be 
important.6 However, when the endothelium is involved 
with atherosclerosis already, it is too late for estrogen to 
exert a beneficial effect.7 Therefore, risk assessment of 
atherosclerosis among postmenopausal women is important 
to enhance primary prevention of CVD and to minimize 
adverse effects of MHT.
CVD is common in patients with chronic kidney disease 
regardless of age and stage of kidney disease. There is now 
evidence that decreased renal function (estimated glomerular 
filtration rate [eGFR] < 60 mL/minute/1.73 m2) is associated 
with cardiovascular events in general populations as well 
as high-risk groups.8 Therefore, screening for early kidney 
function impairment assessed by glomerular filtration rate 
(GFR) may help to detect patients at increased cardiovascular 
risks. Previous our study showed that postmenopausal 
women with decreased renal function are more likely 
to have increased arterial stiffness which reflects the 
severity of vascular damage.9 In addition, arterial stiffness 
measured by brachial-ankle pulse wave velocity (baPWV) 
had high predictive values for coronary atherosclerosis 
in postmenopausal women.10 These results suggest that 
assessing renal function using eGFR can be an economical 
and convenient method for assessment of cardiovascular 
risks in postmenopausal women. 
However, it has not been evaluated whether renal function 
assessed by eGFR may reflect cardiovascular risk in 
postmenopausal women. The purpose of the current study 
is to investigate the association of decreased renal function 
with subclinical coronary atherosclerosis in postmenopausal 
women.
Materials and Methods
1. Participants 
We performed a retrospective review of postmenopausal 
women who visited the health promotion center in Gangnam 
Severance Hospital, Seoul, South Korea, for a routine 
checkup from January 2007 to December 2009. Lifestyle, 
past histories and current medication were checked as same 
as our previous study, as well as the physical examination.11 
We included postmenopausal women over 45 years old 
who underwent blood analysis, baPWV, and 64-row 
multidetector computed tomography (64-MDCT) as parts of 
the routine checkup. Menopause was defined as the absence 
of menstrual periods for 12 months and was confirmed by a 
serum follicle stimulating hormone (FSH) levels > 30 mIU/
mL. Participants with CVD such as myocardial infarction or 
ischemic stroke were excluded. A total of 251 participants 
who met these criteria were finally included in the study.
Smoking history was divided into two categories: current 
and past or never smoker. Alcohol intake was divided into 
drinker and nondrinker. Hormone therapy (HT) use was 
divided into two categories: current or ever and never 
users. Physical activity was divided into active and inactive 
exerciser. Active exerciser was defined as someone who 
exercised three or more times per week for over 30 minutes. 
The study was reviewed and approved by the institutional 
review board of Severance Hospital, Yonsei University 
College of Medicine.
2. Blood analysis
After a 12-hour overnight fast, participants’ blood 
samples were collected through an antecubital vein. Fasting 
plasma glucose, total cholesterol, triglyceride, high-density 
lipoprotein (HDL)-cholesterol, low-density lipoprotein 
(LDL)-cholesterol, and creatinine were measured using a 
7600-110 Chemistry Auto analyzer (Hitachi, Tokyo, Japan).
3. Renal function
The GFR (mL/minute/1.73 m2) was estimated according 
to the Cockcroft-Gault (CG) formula and the modification of 
diet in renal disease (MDRD) formula as follows:
CG = ([140 - age] × body weight [kg] × 0.85)/(serum 
creatinine [mg/dL] × 72), adjusted for body surface area by 
1.73 m2/body surface area
 MDRD = 186 × serum creatinine (mg/dL)-1.154 × age- 0.203 
× 0.742.
Decreased renal function was diagnosed with eGFR less 
than 60 mL/minute.
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4. baPWV measurement
PWV was measured using the automatic waveform 
analyzer (BP-203RPE; Colin Co., Komaki, Japan) in 
accordance with a previously described method.10 The inter-
operator and intra-operator variation were less than 5.0% 
of coefficient. The mean values for the right and left baPWV 
were used for statistical analyses.
5. Coronary artery assessment
Cardiac MDCT was done using a 64-MDCT scanner 
(Philips Brilliance 64; Philips Medical System, Best, the 
Netherlands). The method of performance for the MDCT was 
in accordance with a previous described method.10 Coronary 
atherosclerosis was defined as any size of calcified or non-
calcified atherosclerotic plaque with or without luminal 
narrowing.12
6. Statistical analysis
All the statistical analyses carried out by using the 
SPSS 18.0 software package. (SPSS Inc., Chicago, IL, 
USA). Student’s t-test was applied to compare the general 
characteristics of participants between two groups. 
Univariate and multivariate regression analysis were done 
to find the independent parameters in the presence of 
decreased renal function. Logistic regression analysis was 
done to assess the independent influence of renal function 
on detection of coronary atherosclerosis. A P value less than 
0.05 was considered to be statistically significant.
Results
Table 1 shows general characteristics of decreased renal 
function group and normal renal function group. Age and 
baPWV were significantly higher in decreased renal function 
group than in normal renal function group. Body mass index 
(BMI) was significantly higher in normal renal function 
group than in decreased renal function group (Table 1).
Table 1. Baseline characteristics of the study population stratified according to estimated glomerular filtration rate values
eGFR ≥ 60 (n = 191) eGFR < 60 (n = 60) P value
Age (years) 54.25 ± 4.99 58.80 ± 6.19 < 0.001
BMI (kg/m2) 22.71 ± 2.33 20.86 ± 2.01 < 0.001
SBP (mmHg) 117.47 ± 17.15 116.50 ± 14.19 0.693
DBP (mmHg) 72.71 ± 10.38 72.08 ± 8.37 0.669
FSH (mIU/mL) 80.14 ± 25.78 82.47 ± 22.20 0.529
E2 (pg/mL) 10.16 ± 9.58 9.14 ± 7.11 0.450
Testosterone (nmol/L) 0.68 ± 0.50 0.60 ± 0.38 0.263
Glucose (mg/dL) 90.50 ± 10.20 90.60 ± 8.70 0.944
Cholesterol (mg/dL) 202.21 ± 31.19 210.38 ± 33.62 0.084
HDL-cholesterol (mg/dL) 56.74 ± 13.08 60.53 ± 13.49 0.053
LDL-cholesterol (mg/dL) 128.63 ± 30.04 132.65 ± 31.37 0.421
Triglyceride (mg/dL) 98.85 ± 59.94 97.72 ± 54.52 0.896
WBC count (103/μL) 5.03 ± 1.31 5.10 ± 1.48 0.730
Uric acid (mg/dL) 4.45 ± 0.88 4.24 ± 0.80 0.101
baPWV (cm/sec) 1321.81 ± 156.85 1431.48 ± 163.14 < 0.001
eGFR: estimated glomerular filtration rate, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, FSH: follicle 
stimulating hormone, E2: estradiol, HDL: high density lipoprotein, LDL: low density lipoprotein, WBC: white blood cells, baPWV: brachial-
ankle pulse wave velocity
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Univariate regression analysis revealed that the eGFR 
was significantly positively associated with BMI (β 
= 0.444, P < 0.001) and E2 (β = 0.130, P = 0.040), and 
negatively associated with FSH (β = -0.194, P = 0.002), 
HDL-cholesterol (β = -0.146, P = 0.021) and baPWV (β 
= -0.337, P < 0.001) (Table 2). Association between eGFR 
and baPWV is persisted in normal renal function group, but 
not in decreased renal function group (Fig. 1). Multivariate 
regression analysis revealed that the eGFR was significantly 
positively associated with BMI (β = 0.416, P < 0.001), and 
negatively associated with FSH (β = -0.113, P = 0.043) and 
baPWV (β = -0.352, P < 0.001) (Table 3).
Table 4 shows general characteristics of atherosclerosis 
group and control group. Age and systolic blood pressure 
(SBP) were significantly higher in women with coronary 
atherosclerosis than in normal control women. HDL-
cholesterol and eGFR were significantly lower in women with 
coronary atherosclerosis than in normal control women 
(Table 4). 
Logistic regression analysis was performed to evaluate 
the independence influence of decreased renal function on 
coronary atherosclerosis. Age was significantly associated 
with the presence of coronary atherosclerosis (odds ratio 
[OR] = 1.106, 95% confidence interval [CI] = 1.025-1.193, P 
= 0.009). When the eGFR was considered, HDL-cholesterol 
(OR = 0.951, 95% CI = 0.913-0.991, P = 0.017) and reduced 
eGFR (OR = 7.528, 95% CI = 2.728-20.772, P < 0.001) 
was significantly associated with the presence of coronary 
atherosclerosis (Table 5).
Discussion
We evaluated the relationship between decreased renal 
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Fig. 1. Simple correlation between brachial-ankle pulse wave 
velocity and estimated glomerular filtration rate (eGFR) according 
to eGFR values.
Table 2. Univariate regression analysis for estimated glomerular 
filtration rate
β P value
BMI (kg/m2) 0.444 < 0.001
SBP (mmHg) 0.066 0.298
DBP (mmHg) 0.062 0.326
FSH (mIU/mL) -0.194 0.002
E2 (pg/mL) 0.130 0.040
Testosterone (nmol/L) 0.088 0.167
Glucose (mg/dL) 0.056 0.380
Cholesterol (mg/dL) -0.150 0.098
HDL-cholesterol (mg/dL) -0.146 0.021
LDL-cholesterol (mg/dL) -0.011 0.856
Triglyceride (mg/dL) -0.008 0.903
WBC count (103/μL) -0.022 0.725
Uric acid (mg/dL) 0.087 0.168
baPWV (cm/sec) -0.337 < 0.001
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, FSH: follicle stimulating hormone, E2: estradiol, 
HDL: high density lipoprotein, LDL: low density lipoprotein, WBC: 
white blood cells, baPWV: brachial-ankle pulse wave velocity
Table 3. Multivariate regression analysis for estimated glomerular 
filtration rate
β P value
BMI (kg/m2) 0.416 < 0.001
FSH (mIU/mL) -0.113 0.043
E2 (pg/mL) 0.063 0.236
HDL-cholesterol (mg/dL) -0.018 0.745
baPWV (cm/s) -0.352  < 0.001
BMI: body mass index, FSH: follicle stimulating hormone, E2: 
estradiol, HDL: high density lipoprotein, baPWV: brachial-ankle 
pulse wave velocity
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function and risk of coronary atherosclerosis in healthy 
postmenopausal women. Our study demonstrated that 
decreased eGFR is associated with increased baPWV and 
increased risk of coronary atherosclerosis. This fact was 
confirmed through evaluating with 64-MDCT to check 
coronary atherosclerosis. 
CVD is the number one health risk to women which is 
caused by age, genetic influences, hypertension, diabetes, 
obesity and smoking.13 Along with these risk factors, 
menopause causes women to face many physical as well as 
psychosocial problems.14 To mitigate these postmenopausal 
symptoms, estrogen therapy could be an option in post-
menopausal women, and previous study has reported that 
serum estradiol level might be associated with the degree of 
calcification of coronary artery in postmenopausal women.15 
Besides estrogen therapy, renal function is also alleged to 
Table 4. Baseline characteristics of normal women and women with coronary atherosclerosis
Normal 
(n = 230)
Coronary atherosclerosis
(n = 21) P value
Age (years) 54.98 ± 5.43 59.24 ± 6.45 0.001
BMI (kg/m2) 22.28 ± 2.41 22.10 ± 2.32 0.738
SBP (mmHg) 116.56 ± 16.29 124.62 ± 16.97 0.032
DBP (mmHg) 72.20 ± 9.93 76.48 ± 9.22 0.059
FSH (mIU/mL) 80.72 ± 25.10 80.40 ± 24.10 0.955
E2 (pg/mL) 10.05 ± 9.34 8.43 ± 4.72 0.433
Testosterone (nmol/L) 0.67 ± 0.47 0.62 ± 0.42 0.690
Glucose (mg/dL) 90.55 ± 9.96 90.19 ± 8.66 0.872
Cholesterol (mg/dL) 204.60 ± 31.7 199.43 ± 34.62 0.478
HDL-cholesterol (mg/dL) 58.19 ± 13.33 51.71 ± 11.02 0.032
LDL-cholesterol (mg/dL) 130.19 ± 30.46 121.86 ± 28.49 0.229
Triglyceride (mg/dL) 96.94 ± 56.64 116.52 ± 76.10 0.143
WBC count (103/μL) 5.04 ± 1.36 5.15 ± 1.18 0.720
Uric acid (mg/dL) 4.39 ± 0.87 4.51 ± 0.82 0.549
eGFR (mL/min) 69.30 ± 11.74 58.69 ± 10.28 < 0.001
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, FSH: follicle stimulating hormone, E2: estradiol, HDL: 
high density lipoprotein, LDL: low density lipoprotein, WBC: white blood cells, eGFR: estimated glomerular filtration rate
Table 5. Effects of various factors on coronary atherosclerosis as evaluated in a multiple logistic regression model
OR (95% CI) P value OR (95% CI) P value
Age (years) 1.106 (1.025-1.193) 0.009
SBP (mmHg) 1.013 (0.960-1.068) 0.645 1.026 (0.973-1.081) 0.339
DBP (mmHg) 1.013 (0.923-1.113) 0.779 1.007 (0.917-1.105) 0.889
HDL-cholesterol (mg/dL) 0.975 (0.938-1.013) 0.198 0.951 (0.913-0.991) 0.017
eGFR (mL/min) < 60 7.528 (2.728-20.772) < 0.001
OR: odds ratio, CI: confidence interval, SBP: systolic blood pressure, DBP: diastolic blood pressure, HDL: high density lipoprotein, eGFR: 
estimated glomerular filtration rate
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affect on cardiovascular system. Over the last few years, 
measurements of renal function, increase in urine albumin 
excretion, are known to be powerful prognostic values for 
CVD.16 While the exact pathophysiological mechanisms 
in associations of renal disease and CVD have not been 
completely clarified, changes in intrarenal hemodynamics 
secondary to an increased systemic blood pressure load 
may be tangled with increased capillary leakiness at the 
glomerular level, reflecting on endothelial or atherosclerotic 
process.17
Many others have shown a positive association between 
decreased renal function and atherosclerosis previously.18~20 
CVD is known to be one of the Atherosclerosis was evaluated 
in variable ways, such as examining the presence of plaque, 
peripheral arterial disease, baPWV, and left ventricular 
mass index. Above these studies, one study has presented 
decreased eGFR is significantly associated subclinical 
atherosclerosis.19 Similarly, another cross-sectional study 
also has presented mild impairment of renal function might 
increase arterial stiffness.21 Our results show common 
interrelationship with these previous studies, especially 
about relationship among decrease renal function and 
arterial stiffness, atherosclerosis. Whereas these previous 
studies were targeted on broadly over 50 years old people 
including the healthy and sick, our study focused on healthy 
postmenopausal women only. This makes strength on our 
study, which shows positive correlation between decreased 
renal function and atherosclerotic risk not in high risk group 
but in healthy postmenopausal women group for the first 
time. Also we have strength on that this is the first study 
of arterial stiffness and atherosclerosis to be co-analyzed. 
Additionally we suggest CG equation more sensitive in 
acquiring eGFR than MDRD equation, especially in Koreans. 
We analyzed renal function in both calculations, decreased 
eGFR calculated by MDRD equation also showed positive 
relationship with atherosclerosis. But we had limitation of 
data because most of eGFR by MDRD was higher and over 
60 mL/minute/1.73 m2, leading analysis hardly done. To 
give an account of it, MDRD equation has been different 
according to race. On the basis of this difference, for 
example, modified MDRD equation is used in Japan and 
China. And as known generally, eGFR by MDRD equation 
inaccurately correlates specially in those who have normal 
renal function. 
In practice, there are some limitations in this study. 
First, it has a limitation coming from the nature of 
retrospective study. Although several putative mechanisms 
were mentioned, we could not demonstrate the causal 
relationship between renal function and atherosclerosis. 
Appropriate long-term follow-up and prospective study is 
needed to investigate the effects of decreased renal function 
on development of atherosclerosis in postmenopausal 
women. Second, the relatively small number of participants 
impeded our efforts to arrive at a valid conclusion about 
the association between renal function and atherosclerosis. 
Lastly, eGFR by CG or MDRD has error compared to GFR 
measured by collecting 24 hour urine. In recent years, 
cystatin C is becoming more widely available and provides 
improved estimates of kidney function. Therefore, a newer 
kidney function marker would be required for future clinical 
practice.
Age and/or menopausal period is strongly associated with 
vascular damage (stage of atherosclerosis), and that also 
has been strongly accepted widely, therefore initiating MHT 
before vascular damage may be important factor in reducing 
CVD. Developing screening tool of subclinical atherosclerosis 
should be taken into account importantly to determine 
starting MHT before vascular damage development. To 
our knowledge, eGFR is a simple, cheap and convenient 
screening tool not only filtering high risk group of CVD, but 
also detecting atherosclerosis which could help to determine 
initiating MHT in postmenopausal women.
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